Key facts
- Aprinoia Therapeutics’s last known valuation is $295.5M.
- It has raised $65.0M; the latest was IPO ($5.5M) in Oct 2024.
- Notable investors include IMM Investment, Johnson & Johnson Innovation - JLABS, Woori Venture Partners, Suzhou Yuanfeng Capital Management, ShangPharma Innovation — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Aprinoia Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Aprinoia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aprinoia Therapeutics
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("α-Syn") that are toxic to brain cells.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2015
- Employees
- 20
- Website
- aprinoia.com/
- Ownership
- Privately Held (backing)
Aprinoia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aprinoia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aprinoia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.